Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: A phase II trial

Cancer

Volumn 94, Issue 11, 2002, Pages 2953-2958

  Baur, Martina ^a   Kienzer, Heinz Roland ^a   Schweiger, Johannes ^b   DeSantis, Maria ^a   Gerber, Erich ^b   Pont, Jörg ^a   Hudec, Marcus ^c   Schratter Sehn, Annemarie Ulrike ^b   Wicke, Wolfram ^b   Dittrich, Christian ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b University of Vienna ^*  (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Head and neck carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HUMAN; MALE; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT INDICATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0036604188     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10574     Document Type: Article

References (27)

1. Head and neck cancer
2. Overview of platinum chemotherapy in head and neck cancer
3. A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck
4. A late phase II study of docetaxel (Taxotere) in patients with head and neck cancer (HNC)
5. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck
6. Docetaxel. An active drug for squamous cell carcinoma of the head and neck
7. A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors
8. A promising regimen for treatment of squamous cell carcinoma of the head and neck: Docetaxel and cisplatin
9. Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group
10. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
11. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent
12. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG)
13. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck
14. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin© in recurrent or metastatic squamous cell carcinoma of the head and neck
15. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study
16. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
17. Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer
18. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer
19. Head and neck cancer: Chemotherapy concepts
20. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer
21. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis
22. Reticuloendothelial function in patients with alcoholic liver cirrhosis
23. Energy and protein requirements of patients with chronic liver disease
24. Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with taxotere
25. Factors predicting severe infections in patients treated with docetaxel. An analysis of 111 patients included in a trial by the Scandinavian Breast Cancer Group